What is Roth Capital’s Estimate for CELZ Q2 Earnings?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Equities research analysts at Roth Capital dropped their Q2 2025 EPS estimates for Creative Medical Technology in a research report issued on Wednesday, June 4th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($0.63) for the quarter, down from their previous forecast of ($0.40). The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.85) EPS, FY2027 earnings at $2.19 EPS, FY2028 earnings at $4.37 EPS and FY2029 earnings at $5.76 EPS.

Creative Medical Technology Stock Down 1.2%

Shares of NASDAQ CELZ opened at $2.42 on Monday. The stock has a market capitalization of $6.26 million, a price-to-earnings ratio of -0.64 and a beta of 1.98. The firm has a 50-day moving average price of $2.06 and a 200 day moving average price of $2.74. Creative Medical Technology has a 52 week low of $1.69 and a 52 week high of $6.90.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.31). The company had revenue of $0.00 million for the quarter.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Armistice Capital LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned about 3.38% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is owned by hedge funds and other institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.